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Guidance on the management of Diabetic Ketoacidosis in the exceptional circumstances of the 
COVID-19 pandemic  
Rayman G, Lumb A, Kennon B, Cottrell C, Nagi D, Page E, Voigt D, Courtney H, Atkins H, Platts J, 
Higgins K, Dhatariya K, Patel M, Narendran P, Kar P, Newland‐Jones P, Stewart R, Burr O, Thomas S. 
During the early stages of the COVID-19 pandemic, hospitals in London, the UK epicentre, reported 
an unusually high number of people presenting with COVID-19 disease developing diabetic 
ketoacidosis, hyperosmolar hyperglycaemic state, or a combination of both. Very high doses of 
insulin were often needed to manage the hyperglycaemia.  It has been proposed that these 
metabolic disturbances may result from severe insulin resistance combined with decreased insulin 
secretion due to beta cell dysfunction 1. The increased demand for pumps to deliver inotropes has 
led to concerns of possible shortages of infusion pumps and/or 50 ml syringes being available for 
insulin infusions to manage these hyperglycaemic emergencies.  Concerns were also raised about 
the potential risk of exacerbating ‘lung leak’ in COVID-19 positive patients using the traditional rates 
of fluid replacement for the management of DKA. Clinicians therefore requested that a 
subcutaneous insulin regimen be made available as a backup strategy for managing diabetic 
ketoacidosis and guidance on the fluid replacement regimen. 
In response to these requests the National Diabetes Inpatient COVID-19 Response Group has 
developed guidance on the management of DKA using subcutaneous insulin based on a regimen 
developed by Umpierrez and colleagues in the US2, accompanied by two alternative fluid 
replacement regimens. The first is that from the Joint British Diabetes Societies3 guidance for 
managing typical DKA. The second is a more cautious regimen for COVID-19 positive/suspected 
patients with consideration of a higher rate of fluid replacement if there is significant hypovolaemia 
or acute kidney injury (Figure 1). Importantly, clinical judgement, frequent senior review, and regular 
monitoring of fluid balance and oxygen saturations are advised. The regimen recommends using
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rapid acting insulin analogues.  Given the need to reduce the time the health professional is in direct 
contact with the patient a 4 hourly dosing schedule has been recommended with the dose 
calculated on body weight to equate to a similar quantity of insulin that would have been delivered 
by an insulin infusion. Finally, as with other guidance we recommend continuing or starting a basal 
insulin alongside.   
We hope that most teams will not find it necessary to use the subcutaneous insulin route to manage 
DKA, but we understand that this regimen has been welcomed by some working in less well-
resourced countries.  
 
1. Practical recommendations for the management of diabetes in patients with COVID-19.  
Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, et al.  Lancet 
Diabetes Endocrinol 2020 Published Online, April 23, 2020, https://doi.org/10.1016/: S2213-
8587(20)30152-2 
2. Andrade-Castellanos CA, Colunga-Lozano LE, Delgado-Figueroa N, Gonzalez-Padilla DA. 
Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis. Cochrane Database 
Syst Rev. 2016 Jan 21;(1) 
3. Savage M W, Dhatariya K K, Kilvert A, Rayman G et al. Joint British Diabetes Societies 






COncise adVice on Inpatient 
Diabetes (COVID:Diabetes): 
GUIDELINE FOR MANAGING DKA 
USING SUBCUTANEOUS INSULIN
(where intravenous insulin infusion is not possible)
NATIONAL INPATIENT DIABETES COVID-19 RESPONSE GROUP*
 o For use in Covid-19 suspected/positive people and those without Covid-19 disease when 
diagnosis of DKA has been confirmed (see  COVID: Diabetes Front Door Guidance)  
This approach is NOT recommended where:
  Mixed DKA/Hyperosmolar state (osmolality greater than 320 - osmolality  
= [2 x Na] + Urea + Glucose)
  The person is pregnant
  Severe metabolic derangement (e.g. pH less than 7.0, OR bicarbonate less than 10 mmol/l, 
OR potassium less than 3.5 mmol/l)
  Significant other co-morbidity (e.g. acute coronary syndrome, CKD stage 4 or 5, end-stage 
liver disease)
  Conscious level impaired
In these situations, help should be sought early from the specialist diabetes team and teams 
should refer to their local DKA protocol.
Aims of treatment:
 › Fall in ketones of 0.5 mmol/l/hour while
 › Maintaining glucose at a safe level without hypoglycaemia
 » Target glucose range is 6 - 14 mmol/l 
 » Additional glucose is required (by IV infusion – see Fluid Replacement over) when glucose is lower 
than 14 mmol/l 
  Remember, euglycaemic DKA – where glucose levels are normal – can occur in pregnancy or in 
those using SGLT2 inhibitors
Targets of treatment:
 o Ketones less than 0.6 mmol/l
 o pH greater than 7.3
*NATIONAL INPATIENT DIABETES COVID-19 RESPONSE GROUP:
Professor Gerry Rayman (Chair), Dr Alistair Lumb, Dr Brian Kennon, Chris Cottrell, Dr Dinesh Nagi, Emma Page, Debbie Voigt, 
Dr Hamish Courtney, Helen Atkins, Dr Julia Platts, Dr Kath Higgins, Professor Ketan Dhatariya, Dr Mayank Patel, Dr Parth 
Narendran, Professor Partha Kar, Philip Newland-Jones, Dr Rose Stewart, Dr Stephen Thomas, Dr Stuart Ritchie 





 o ALWAYS START/CONTINUE LONG-ACTING 
INSULIN WHEN TREATING DKA
 › If using regular injectable long-acting 
insulin this should be continued
 › If not previously using basal insulin  
initiate a dose of 0.15* units/kg/day  
(involve the local diabetes team at the 
earliest opportunity)
If using a personal insulin pump either: 
1. Continue basal insulin rate via pump 
if person can safely manage this 
themselves. The pump infusion set should 
be changed by the patient (it may be an 
infusion set problem that caused DKA) 
OR
2. Switch to sc basal insulin regime if the 
person is not able to safely manage their 
own pump:
 › Find the usual total daily basal 
insulin dose and use the same dose 
of injectable basal insulin (the 
patient will be able to find this dose 
from the pump)
 › If unable to find total basal insulin 
dose from pump then give a total daily 
basal insulin dose of 0.25* units/kg
 › Options are twice daily Levemir®  
or once daily Lantus® / Abasaglar® /
Semglee®
* Different basal dose depending on insulin 
naive or previous insulin use
RAPID-ACTING INSULIN
 o 4 HOURLY SUBCUTANEOUS DOSES OF 
RAPID-ACTING INSULIN ANALOGUE 
(NOVORAPID® /HUMALOG® /APIDRA®)
Aiming for a reduction in ketones of at least 0.5 
mmol/l/hour (2 mmol/l over 4 hours)
 › Initial dose of 0.4 units/kg every 4 hours. This 
dose may appear large however is equivalent to 
the IV dose used in standard DKA management
 › Reduce to 0.2 units/kg every 4 hours once 
glucose less than 14 mmol/l
 › Continue until ketones less than 0.6 mmol/l
If ketones not falling as expected:
 › Increase rapid acting insulin dose to 0.5 
units/kg every 4 hours
 › Contact the diabetes specialist team
 › Consider switching to iv insulin if infusion 
pump available
POTASSIUM
  The effect of Covid-19 disease on 
potassium regulation remains unknown, 
and so potassium replacement should 
follow standard protocols and be guided 
by 2 hourly monitoring
MONITORING IMPACT OF TREATMENT
 › Glucose and ketones - check at least 2 hrly
 › Fluid balance - record hrly, regular review and 
adjustment according to clinical condition
 › Oxygen saturations - regular assessment 
as a potential marker of fluid overload
ONCE TREATMENT TARGETS ARE ACHIEVED:
If the person is already treated with insulin
 › Transfer back onto usual regimen
 » If on subcutaneous insulin injections
• Long-acting insulin should have been 
continued – ensure this is the case
• Add rapid-acting insulin according to 
the usual regimen before meals
• Correction doses can be used according 
to the “Guidance for managing inpatient 
hyperglycaemia” document 
 » If using a personal insulin pump
• The person will need to be well enough 
to reinstate their pump and manage 
their insulin regimen themselves
• Ensure pump started within 3 hrs of 
subcutaneous rapid acting insulin dose
If the person was not previously on insulin
 › Administer long-acting insulin as above 
(Basal Insulin section) and use the “Guidance 
for managing inpatient hyperglycaemia” 
document for correction doses
  Involve your local diabetes team
  ALWAYS monitor glucose and ketones 
initially 4 hourly following transfer to 
‘usual’ insulin regimen to ensure ketones 
remain lower than 1.5 mmol/l and blood 
glucose is within target range (6 – 
14mmol/l)
FLUID REPLACEMENT
 o FLUID SHOULD BE REPLACED INTRAVENOUSLY
For general guidance regarding intravenous fluid 
replacement see local guidance or JBDS guidance 
available here.
  Initial resuscitation – if systolic BP less than 
90 mmHg infuse 500mls 0.9% saline bolus 
over 15 minutes. Repeat if systolic BP remains 
below 90 mmHg. Seek senior support if 
requiring more than 1 bolus of this sort.
Standard rate of fluid replacement with 0.9% 
saline (note slower rate should be considered 
in those aged 18-25 and over 70, and who are 
pregnant or who have cardiac or renal failure)
RATE (ML/HR)
1st litre (given over 1 hr) 1000
2nd litre (given over 2 hr) 500
3rd litre (given over 2 hr) 500
4th litre (given over 4 hr) 250
5th litre (given over 4 hr) 250
If a more cautious approach is required in 
COVID-19 positive/suspected, after an initial 
fluid bolus of 250ml in 15 minutes, the table 
below is a starting point only, and aims to 
avoid excessive fluid replacement. Use clinical 
judgment, frequent senior review and consider a 
higher rate of fluid replacement if significantly 
hypovolaemic/AKI:
WEIGHT (KG) RATE OF 0.9% SODIUM CHLORIDE INFUSION (MLS/HR)










Over 100 170 155
Remember: Glucose-containing fluid (e.g. 10% 
glucose at 125 ml/hour) should be infused when 
the glucose is less than 14 mmol/l and reviewed 
with insulin prescription when ketones less 
than 0.6 mmol/l. The 10% glucose usually runs 
alongside the 0.9% sodium chloride solution.
For euglygaemic DKA 10% glucose should be 
used as the resuscitation fluid.
